Galapagos: Publication of the annual report

Today Galapagos NV (Euronext & NASDAQ: GLPG) published its Annual Report for the financial year 2016. 

The annual report for the financial year 2016, including a review of figures and performance, is available online on and can also be downloaded as PDF.


Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises Phase 3, Phase 2, Phase 1, pre-clinical, and discovery programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. We have discovered and developed filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory indications to patients all over the world. Galapagos is focused on the development and commercialization of novel medicines that will improve people's lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 510 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia.

Interested in a regular update of the Life Sciences and biotech sector in Flanders?